Essilor (ESLOY), Luxottica (LUX) Ink Mega-Merger Deal; Opko Health (OPK) Eyeing Opportunity in RXi Pharma (RXII)


Luxottica Group S.p.A. (NYSE:LUX) and French optical-lens maker Essilor International SA (OTCMKTS:ESLOY) said Monday that they have agreed to merge in an all-share deal to create EssilorLuxottica – an eyewear giant with a market value of approximately EUR46.3 billion ($49.16 billion) and revenue of over EUR15 billion -.

LUX stock closed at $52.42, up $0.44 (or +0.85%) with a total volume of 51,962 shares traded on Friday.

Luxottica Group, which provides fashion, luxury, sports, and performance eyewear worldwide, has 479.79M shares outstanding and LUX stock 52-week range is from $44.85 to $63.62 per share. At close on Friday, the maker of Ray-Ban sunglasses had a market capitalization of $25.67B.



RXi Pharmaceuticals Corp. (Nasdaq:RXII) stock surged 6.07% (or +$0.04) to $0.75 on Friday’s trading session after multinational pharmaceutical Opko Health, Inc. (Nasdaq:OPK) reported to the U.S. Securities and Exchange Commission (SEC) the ownership of 446,360 shares (5.11% stake) of the company.

12.39M shares of RXi changed hands during the day, representing a large increase in activity versus its average volume (3m) of 1.02M shares.

RXi Pharmaceuticals, a clinical-stage RNAi company, has 8.73M shares outstanding, market capitalization (intraday) of $6.53M and RXII stock one-year range is between $0.69 and $3.50 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at